Cisplatin, ara-C and etoposide (PAE) in the treatment of recurrent childhood brain tumors

Brian J. Corden, Lewis C. Strauss, Thomas Killmond, Benjamin S. Carson, Moody D. Wharam, Ashok J. Kumar, Steven Piantadosi, Pam A. Robb, Peter C. Phillips

Research output: Contribution to journalArticlepeer-review

Abstract

Sixteen patients with recurrent childhood brain tumors were treated with intravenous cisplatin, cytosine arabinoside and etoposide (PAE), daily for three days every three to four weeks. Objective responses were observed in 6 of 15 evaluable patients and an additional six patients had stable disease for > 6 months. The tumor-specific response rate for astrocytoma/glioma was 3 of 7 and for medulloblastoma was 2 of 4. The mean progression-free interval was 11.0 months and the hazard rate for progression was 0.085 per patient-month of observation. The most common toxicities were neutropenia and thrombocytopenia. Clinically significant ototoxicity wasidentified in 7 patients. The activity of PAE chemotherapy for recurrent childhood brain tumors warrants further investigation.

Original languageEnglish (US)
Pages (from-to)57-63
Number of pages7
JournalJournal of neuro-oncology
Volume11
Issue number1
DOIs
StatePublished - Aug 1 1991

Keywords

  • chemotherapy
  • childhood brain tumor

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Fingerprint Dive into the research topics of 'Cisplatin, ara-C and etoposide (PAE) in the treatment of recurrent childhood brain tumors'. Together they form a unique fingerprint.

Cite this